Please provide your email address to receive an email when new articles are posted on . The FDA has approved a self-administered injection of the leukocyte growth factor tbo-filgrastim for patients ...
New Granix Syringes Approved for Self-Administration Teva Oncology announced the launch of a new single-use pre-filled syringe for self-administration for Granix (tbo-filgrastim). Teva Oncology ...
The pediatric approval was supported by evidence from studies in adults with additional safety and pharmacokinetics data from a single-arm trial of 50 pediatric patients with solid tumors treated with ...
Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information ...
JERUSALEM — Teva Pharmaceutical today announced that the Food and Drug Administration has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the ...
Teva’s Neupogen biosimilar Granix has been granted FDA approval for updated indication and vial presentation, which it said would provide pediatric patients with new treatment options.
The FDA approves Teva Pharmaceutical Industries' (NYSE:TEVA) Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. This will enable physicians to prescribe the product ...
Teva Pharmaceuticals announced that FDA approved Granix injection for self-administration in patients. Teva Pharmaceuticals announced on Dec. 23, 2014 that it received FDA approval of Granix ...
Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback